BioSpace News Archive

On Friday, January 27, 2023, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), filed its financial results for the fiscal year ended February 28, 2022.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’s next generation DaggerTM platform technology at the Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy Keystone Symposia in Banff, Alberta, Canada.

FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, announced they are the fastest rising biotech offering in StartEngine’s history surpassing $1 million of new investments on the first day of its Reg CF offering.

MDxHealth SA, a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40,000,000 of American Depositary Shares in a registered public offering.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023.

Cytokinetics, Incorporated announced that on January 31, 2023 it granted stock options to purchase an aggregate of 87,600 shares of common stock to 13 new employees, whose employment commenced in January 2023, as a material inducement to their employment.

Paratek Pharmaceuticals, Inc. announced that on January 31, 2023, the Company granted stock options to four new employees of the Company.

Vera Therapeutics, Inc. announced that it has commenced a public offering, subject to market and other conditions, to issue and sell $75.0 million of shares of its Class A common stock.

AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).

Hologic, Inc. announced the Company’s financial results for the fiscal first quarter ended December 31, 2022.